{
  "input": {
    "mode": "report_and_evolve",
    "query": {
      "entity": "Gastrointestinal epithelial barrier disorders",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_budesonide",
          "name": "Budesonide"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_mesalamine",
          "name": "Mesalamine"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_pentasa",
          "name": "Pentasa"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_sulfasalazine",
          "name": "Sulfasalazine"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_prednisone",
          "name": "Prednisone"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_tofacitinib",
          "name": "Tofacitinib"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_azathioprine",
          "name": "Azathioprine"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_mercaptopurine",
          "name": "Mercaptopurine"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_vedolizumab",
          "name": "Vedolizumab"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "scores": [
      {
        "hypothesis_id": "H1",
        "score": 0.57,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Budesonide risks",
              "pro": [
                "drug_budesonide"
              ],
              "con": [
                "n_adv_budesonide"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Budesonide acts on TNF-alpha, relevant to inflammatory response."
          ],
          "safety_risk": [
            "Concerns about potential adverse effects related to side pathways."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Specific adverse effects and their relevance to efficacy need further verification."
        ]
      },
      {
        "hypothesis_id": "H2",
        "score": 0.53,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Mesalamine risks",
              "pro": [
                "drug_mesalamine"
              ],
              "con": [
                "n_adv_mesalamine"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Mesalamine acts on TNF-alpha, related to inflammatory response."
          ],
          "safety_risk": [
            "Concerns about potential adverse effects due to risk pathways."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Specific adverse effects and their implications for treatment efficacy need verification."
        ]
      },
      {
        "hypothesis_id": "H3",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Pentasa risks",
              "pro": [
                "drug_pentasa"
              ],
              "con": [
                "potential adverse effects identified."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Pentasa acts on TNF-alpha, relevant for treating gastrointestinal disorders."
          ],
          "safety_risk": [
            "Potential adverse effects from risk pathways need consideration."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Implications of side effects on efficacy still need to be determined."
        ]
      },
      {
        "hypothesis_id": "H4",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Sulfasalazine risks",
              "pro": [
                "drug_sulfasalazine"
              ],
              "con": [
                "identified potential adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Sulfasalazine acts on TNF-alpha, applicable for gut inflammation."
          ],
          "safety_risk": [
            "Adverse effects associated with risk pathways need to be accounted."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Safety profile and its impact on treatment outcomes need further exploration."
        ]
      },
      {
        "hypothesis_id": "H5",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Prednisone risks",
              "pro": [
                "drug_prednisone"
              ],
              "con": [
                "adverse effects through side pathways."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Prednisone's action on TNF-alpha is relevant for inflammatory disorders."
          ],
          "safety_risk": [
            "Adverse effects from risk pathways require attention."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Effects of side effects on the drug's efficacy should be assessed further."
        ]
      },
      {
        "hypothesis_id": "H6",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.85,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.45,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Infliximab risks",
              "pro": [
                "drug_infliximab"
              ],
              "con": [
                "risk against adverse outcomes."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Infliximab directly acts on TNF-alpha, effective for inflammatory conditions."
          ],
          "safety_risk": [
            "Potential adverse effects from risk pathways exist."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Adverse effect implications need to be examined further."
        ]
      },
      {
        "hypothesis_id": "H7",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.85,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.45,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adalimumab risks",
              "pro": [
                "drug_adalimumab"
              ],
              "con": [
                "indicated potential adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Adalimumab targets TNF-alpha, applicable for conditions involving inflammation."
          ],
          "safety_risk": [
            "Adverse effects related to risk pathways need addressing."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Implications of adverse effects on treatment effectiveness should be evaluated."
        ]
      },
      {
        "hypothesis_id": "H8",
        "score": 0.57,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 3.0,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Ustekinumab risks",
              "pro": [
                "drug_ustekinumab"
              ],
              "con": [
                "potential adverse outcomes."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Ustekinumab modulates pathways relevant to inflammatory responses."
          ],
          "safety_risk": [
            "Risks linked to this drug need to be weighed."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Long-term safety and adverse effect considerations remain to be clarified."
        ]
      },
      {
        "hypothesis_id": "H9",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.65,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 3.0,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Tofacitinib risks",
              "pro": [
                "drug_tofacitinib"
              ],
              "con": [
                "linked to potential adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Tofacitinib modulates relevant inflammatory pathways."
          ],
          "safety_risk": [
            "Potential adverse effects necessitate attention."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Impact of side effects on the drug's efficacy remains to be evaluated."
        ]
      },
      {
        "hypothesis_id": "H10",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 3.0,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Azathioprine risks",
              "pro": [
                "drug_azathioprine"
              ],
              "con": [
                "highlighted potential adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Azathioprine modulates immune responses."
          ],
          "safety_risk": [
            "Concerns about adverse outcomes tie into risk pathways."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Determining the risk-benefit ratio remains essential."
        ]
      },
      {
        "hypothesis_id": "H11",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 3.0,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Mercaptopurine risks",
              "pro": [
                "drug_mercaptopurine"
              ],
              "con": [
                "identified adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Mercaptopurine has associations with immune modulation."
          ],
          "safety_risk": [
            "Emerging adverse effects need consideration."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Additional evaluations of safety profiles are required."
        ]
      },
      {
        "hypothesis_id": "H12",
        "score": 0.54,
        "components": {
          "mechanism_fit": 0.75,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.4,
          "safety_risk": 0.25,
          "graph_bonus": 0.05,
          "conflict_penalty": 0.25
        },
        "graph_signals": {
          "support_weight": 5.2,
          "contradiction_weight": 1.7,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Vedolizumab risks",
              "pro": [
                "drug_vedolizumab"
              ],
              "con": [
                "potential risk of adverse effects."
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Vedolizumab acts on activated lymphocytes, relevant for inflammation."
          ],
          "safety_risk": [
            "Potential adverse effects must be evaluated."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Effectiveness influenced by adverse reactions warrants additional study."
        ]
      }
    ],
    "ranking": [
      "H1",
      "H8",
      "H3",
      "H4",
      "H6",
      "H7",
      "H12",
      "H2",
      "H5",
      "H9",
      "H10",
      "H11"
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_budesonide",
          "type": "Drug",
          "label": "Budesonide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_mesalamine",
          "type": "Drug",
          "label": "Mesalamine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_pentasa",
          "type": "Drug",
          "label": "Pentasa",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_sulfasalazine",
          "type": "Drug",
          "label": "Sulfasalazine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_prednisone",
          "type": "Drug",
          "label": "Prednisone",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tofacitinib",
          "type": "Drug",
          "label": "Tofacitinib",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_azathioprine",
          "type": "Drug",
          "label": "Azathioprine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_mercaptopurine",
          "type": "Drug",
          "label": "Mercaptopurine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_vedolizumab",
          "type": "Drug",
          "label": "Vedolizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_tg",
          "type": "Target",
          "label": "TNF-alpha",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_pb",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_gastrointestinal_barrier_disorders",
          "type": "Disease",
          "label": "Gastrointestinal epithelial barrier disorders",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_budesonide",
          "type": "Target",
          "label": "OffTargetBudesonide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_budesonide",
          "type": "Pathway",
          "label": "RiskPathBudesonide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_budesonide",
          "type": "Phenotype",
          "label": "AdverseEffectBudesonide",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_mesalamine",
          "type": "Target",
          "label": "OffTargetMesalamine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_mesalamine",
          "type": "Pathway",
          "label": "RiskPathMesalamine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_mesalamine",
          "type": "Phenotype",
          "label": "AdverseEffectMesalamine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Budesonide",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Mesalamine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Pentasa",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Sulfasalazine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Prednisone",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Infliximab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Adalimumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Tofacitinib",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Azathioprine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Mercaptopurine",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Vedolizumab",
          "attrs": {
            "agent": "PI"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_budesonide",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "已知对炎症反应有抑制作用"
        },
        {
          "source": "drug_mesalamine",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "同类药理作用"
        },
        {
          "source": "drug_pentasa",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "用于相应疾病的临床证据"
        },
        {
          "source": "drug_sulfasalazine",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "用于治疗肠道炎症"
        },
        {
          "source": "drug_prednisone",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "免疫抑制剂，有效于炎症"
        },
        {
          "source": "drug_infliximab",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "靶向TNF-alpha，有效抑制炎症"
        },
        {
          "source": "drug_adalimumab",
          "target": "n_tg",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "靶向TNF-alpha，有效抑制炎症"
        },
        {
          "source": "drug_ustekinumab",
          "target": "n_pb",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "作用于特定的免疫通路"
        },
        {
          "source": "drug_tofacitinib",
          "target": "n_pb",
          "relation": "modulates",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "口服的JAK抑制剂，有调节作用"
        },
        {
          "source": "drug_azathioprine",
          "target": "n_pb",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "免疫抑制剂，影响炎症过程"
        },
        {
          "source": "drug_mercaptopurine",
          "target": "n_pb",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "免疫抑制及抗炎作用"
        },
        {
          "source": "drug_vedolizumab",
          "target": "n_pb",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "针对活化的淋巴细胞，调节炎症过程"
        },
        {
          "source": "n_tg",
          "target": "n_pb",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "TNF-alpha 在炎症通路中起关键作用"
        },
        {
          "source": "n_pb",
          "target": "d_gastrointestinal_barrier_disorders",
          "relation": "causes",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "通路与肠道屏障疾病密切相关"
        },
        {
          "source": "drug_budesonide",
          "target": "n_ot_budesonide",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能存在旁路效应"
        },
        {
          "source": "n_ot_budesonide",
          "target": "n_rp_budesonide",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能的风险通路"
        },
        {
          "source": "n_rp_budesonide",
          "target": "n_adv_budesonide",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良反应"
        },
        {
          "source": "n_adv_budesonide",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若风险成立，将削弱假设的有效性"
        },
        {
          "source": "drug_mesalamine",
          "target": "n_ot_mesalamine",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "同样可能存在旁路"
        },
        {
          "source": "n_ot_mesalamine",
          "target": "n_rp_mesalamine",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "与风险路径相关"
        },
        {
          "source": "n_rp_mesalamine",
          "target": "n_adv_mesalamine",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "产生不良表型"
        },
        {
          "source": "n_adv_mesalamine",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "潜在风险对假设产生反驳"
        }
      ],
      "round_index": 4
    },
    "history": {
      "round": 4
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_budesonide",
          "name": "Budesonide"
        },
        "score": 0.57,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "Budesonide's action on TNF-alpha is crucial for inflammatory response.",
          "Potential adverse effects need further investigation."
        ],
        "caveats": [
          "Safety profile and specific side effects are yet to be thoroughly assessed."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_mesalamine",
          "name": "Mesalamine"
        },
        "score": 0.53,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "Indication for inflammatory response treatment is valid.",
          "Risks related to side pathways require verification."
        ],
        "caveats": [
          "Long-term efficacy and safety implications need clarity."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_pentasa",
          "name": "Pentasa"
        },
        "score": 0.55,
        "graph_snapshot_ref": "GE_H3_round4",
        "key_assumptions": [
          "Mechanism aligns with the treatment of gastrointestinal disorders.",
          "Adverse effects from risk pathways must be carefully monitored."
        ],
        "caveats": [
          "Impact of side effects on overall treatment outcomes remains uncertain."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_sulfasalazine",
          "name": "Sulfasalazine"
        },
        "score": 0.55,
        "graph_snapshot_ref": "GE_H4_round4",
        "key_assumptions": [
          "Effectiveness in treating gut inflammation is established.",
          "Safety and adverse treatment reactions need further evaluation."
        ],
        "caveats": [
          "Short and long-term safety profiles are pivotal for practice."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_prednisone",
          "name": "Prednisone"
        },
        "score": 0.52,
        "graph_snapshot_ref": "GE_H5_round4",
        "key_assumptions": [
          "Immunosuppressive properties relevant to inflammation management.",
          "Side effects must be quantified against treatment benefits."
        ],
        "caveats": [
          "Efficacy amid safety concerns requires deeper exploration."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H6",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "score": 0.55,
        "graph_snapshot_ref": "GE_H6_round4",
        "key_assumptions": [
          "Direct action on TNF-alpha is effective for inflammation.",
          "Potential adverse effects associated with this treatment must be examined."
        ],
        "caveats": [
          "Real-world effectiveness against observed side effects needs clarity."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H7",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "score": 0.55,
        "graph_snapshot_ref": "GE_H7_round4",
        "key_assumptions": [
          "Targeting TNF-alpha is valid for inflammatory conditions.",
          "Risks related to treatment efficacy must be addressed."
        ],
        "caveats": [
          "Adverse events could impact treatment success metrics."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H8",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "score": 0.57,
        "graph_snapshot_ref": "GE_H8_round4",
        "key_assumptions": [
          "Modulates immune pathways linked to inflammatory responses.",
          "Long-term safety risks need assessment."
        ],
        "caveats": [
          "Adverse effect profiles and their management require careful study."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H9",
        "candidate": {
          "id": "drug_tofacitinib",
          "name": "Tofacitinib"
        },
        "score": 0.52,
        "graph_snapshot_ref": "GE_H9_round4",
        "key_assumptions": [
          "Relevant modulating pathways should be effective.",
          "Risks related to therapy demand thorough monitoring."
        ],
        "caveats": [
          "Need to evaluate comprehensive effects and potential adverse outcomes."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H10",
        "candidate": {
          "id": "drug_azathioprine",
          "name": "Azathioprine"
        },
        "score": 0.52,
        "graph_snapshot_ref": "GE_H10_round4",
        "key_assumptions": [
          "Modulates inflammation-related immune responses effectively.",
          "Risks must be carefully considered in the therapy context."
        ],
        "caveats": [
          "Evaluating the risk-benefit ratio remains essential."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H11",
        "candidate": {
          "id": "drug_mercaptopurine",
          "name": "Mercaptopurine"
        },
        "score": 0.52,
        "graph_snapshot_ref": "GE_H11_round4",
        "key_assumptions": [
          "Relevance in immune modulation is established.",
          "Need for ongoing review of emerging safety concerns."
        ],
        "caveats": [
          "Evaluation of observed side effects against treatment outcomes is critical."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H12",
        "candidate": {
          "id": "drug_vedolizumab",
          "name": "Vedolizumab"
        },
        "score": 0.54,
        "graph_snapshot_ref": "GE_H12_round4",
        "key_assumptions": [
          "Mechanism relevant for inflammation targeting.",
          "Safety considerations must be integrated into practice."
        ],
        "caveats": [
          "Effectiveness affected by potential adverse reactions must be closely monitored."
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug acts_on TNF-alpha → Inflammatory Response Pathway → Gastrointestinal epithelial barrier disorders",
          "reason": "Mechanistic pathways show alignment with treatment hypotheses."
        }
      ],
      "remaining_gaps": [
        "Longitudinal safety outcomes and specific adverse reaction links need to be clarified."
      ]
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "明确每种药物的潜在不良反应，强调安全性评估的重要性。"
      },
      {
        "role": "Skeptic",
        "patch": "针对不良事件提供可证伪的具体观察，提示在疗效与安全性之间的平衡。"
      },
      {
        "role": "Explorer",
        "patch": "关注药物组合的效果，审视历史案例中与现有疗法的比较。"
      }
    ],
    "heuristics": [
      {
        "when": "Gastrointestinal epithelial barrier disorders",
        "then": "审视各药物安全性与有效性的历史及当前数据，特别关注长期影响与不良反应。"
      }
    ]
  }
}